Corticosteroids for Septic Shock: Hemodynamic and Mortality Outcomes

Abstract

Introduction: Despite decades of research, corticosteroid use in septic shock remains controversial. This review synthesizes evidence on whether corticosteroids improve mortality and shock reversal.

Methods: Systematic review of randomized placebo-controlled trials of hydrocortisone, with or without fludrocortisone, in adults with septic shock. Primary outcome was all-cause mortality at 28 days. Secondary outcomes included shock reversal (discontinuation of vasopressors) and superinfection incidence.

Results: Eleven trials (7,894 patients) were included. Corticosteroids reduced 28-day mortality by 9% (relative risk 0.91) in the pooled analysis. Shock reversal occurred faster, with vasopressor-free days increasing by a mean of 2.8 days. Superinfection risk increased by 14%, primarily hyperglycemia-related infections and urinary tract infections. Effect size was larger in patients with higher baseline illness severity.

Discussion: Corticosteroids likely exert benefit by modulating the excessive inflammatory response and improving vascular responsiveness to catecholamines. The increased infection risk requires vigilance and may outweigh benefits in lower-risk patients. Heterogeneity in steroid type, dose, and weaning protocols limits direct comparability between trials. Most trials used hydrocortisone 200 mg daily for 5-7 days.

Conclusions: Corticosteroids confer a modest mortality benefit in septic shock at the cost of increased superinfections. Therapy should target patients with refractory shock requiring high-dose vasopressors.